Chambers Review
Provided by Chambers
Intellectual Property - France
What the Team is Known For
Schertenleib Avocats enters the rankings this year thanks to renown for its specialisation in high-stakes intellectual property disputes. The team advises on patent infringement, trade secrets and FRAND policy issues, and is active across the life sciences, technology and medical device industries. The law firm represents clients before French and international courts.
Strengths
I appreciated their strong reactivity and ability to simplify complex topics, enabling the business team to make the best possible decisions. We received regular updates and guidance.
Over the last decade, the firm has expanded to build an impressive and highly experienced team.
They are able to solve the most complex issues and come up with suitable solutions thanks to their strong expertise, broad experience and comprehensive market knowledge.
Schertenleib is the go-to for pharmaceutical patent litigation. The advice is always on point, pragmatic and timely.
Work Highlights
Schertenleib Avocats represented Viatris in a preliminary injunction application proceeding against Novartis.
Notable practitioners
Dual-qualified in France and in England and Wales, Denis Schertenleib is well versed in advising on contentious matters involving infringement actions, validity claims and revocation proceedings. He is frequently retained by clients from the pharmaceutical and life sciences sectors.
He is a litigator who will push beyond the boundaries of what has been done before in the interest of the client. He is very strategic, highly innovative and very clever. He is a confident litigator.
He is characterised by his high-quality legal advice, which is always very reliable and prompt.
He is an exceptional French lawyer and he is also qualified as an English solicitor. This helps him translate the French civil system to clients more accustomed to common law systems.
I am extremely satisfied with the support and collaboration with Denis.
Denis is excellent all round.